CEO Witty's 2017 Exit Could Hasten Glaxo's Consumer Business Decision
This article was originally published in The Tan Sheet
Glaxo CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change. His biggest legacy could be the multi-asset swap he orchestrated with Novartis in 2014 that created a consumer health care JV with the Swiss firm.
You may also be interested in...
P&G's activist investor Trian Fund Management is known for pressuring big companies to break up. The OTC business would likely have plenty of potential buyers.
CEO changes are underway across big pharma and biotech, marking a time of substantial leadership transition for the industry. New CEOs are usually insiders, but external hires appear to be more willing to implement change to improve shareholder returns, according to an analysis from Leerink.
Andrew Witty tells analysts Glaxo is strong in areas critical to success in the consumer health products space: margin, scale and potential OTC switches. The Flonase Allergy Relief OTC switch shows "nobody is switching products better than GSK," he says.